Share

Synergy between cyclin inhibitors and trabectedin in soft tissue sarcoma and breast cancer cell models

Project objectives

  • To evaluate the potential synergistic antitumor effect of cyclin inhibitors (CDKi) and trabectedin in different cellular models of soft tissue sarcoma
  • Analyze the potential synergistic antitumor effect of CDKi and trabectedin in different breast cancer cell models
  • To evaluate the potential synergistic antitumor effect of CDKi and new trabectedin analogue molecules (lurbinectedin and PM54) in the same cellular models
  • To evaluate the potential synergistic antitumor effect of CDKi with other chemotherapy drugs that have different mechanisms of action

Start and end date
October 2021 – ongoing (July 2024 approximate end date)

Project Manager
Bruno Vincenzi (PI)

Coordinating institution of the project
Università Campus Bio-Medico di Roma

Other Institutions involved
  • RCCS Rizzoli Orthopedic Institute
  • IRCCS National Cancer Institute Foundation

Primary funding source
PharmaMar SA
2023© Università Campus Bio-Medico di Roma, Via Álvaro del Portillo, 21 - 00128 Rome, Tel. +39 06.22541.1, Fax +39 06.22541.456, VAT number: 048 020 51 005, Fiscal Code: 97087620585
QUICK LINKS
L'Università Campus Bio-Medico di Roma promotes integrated teaching and research structures, pursuing the good of the person as the main aim of its activities.
magnifiercrossmenuchevron-downchevron-leftchevron-right